Response Rate & Risk Profile: Interpreting Early Efficacy in High-Risk mTNBC Patients

Early relapse patterns reveal a high-risk patient population — and that context matters when interpreting trial outcomes. Dr. Garrido-Castro explains how DFI, brain metastases, and biology shaped the differences between the two studies.

She also breaks down the major response-rate gap: dato-DXd at 63% vs 29% with chemotherapy, and why rapid responses may be critical in patients with visceral disease.

#TNBC #BreastCancer #Oncology #ADCtherapy #TROP2 #TROPIONBreast02 #ASCENT03 #CancerResearch #CHM

–

Thanks for watching!

Our podcasts are also available on:
• Spotify - https://spotf.fi/chm-podcast
• Amazon Music - https://amazn.so/chm-podcast
• Apple Podcast - https://podcasts.apple.com/us/podcast...
• Castbox - https://castbox.fm/vh/6735434
• Goodpods - https://goodpods.com/profile/chm-111066
• iHeartRadio - https://iheart.com/podcast/291542082
• Pocket Casts - https://pca.st/3ncdh11o

–

Community Health Media (CHM) is your full service healthcare communications partner, combining our production expertise with targeted multi-channel campaigns. We connect companies and healthcare brands with key opinion leaders, patients, and consumers through compelling content and live experiences.

We’re an integrated marketing company that produces world-class content and curated peer to peer live experiences.

We specialize in:
• Peer to peer interviews, panels & round-tables
• Curated live events & conferences
• Professional in-depth content & research updates
• Interactive learning modules & webinars
• Live & on-demand webcasts & podcasts

Learn more about us here - https://communityhealth.media